ArticleDiscover oncology2025
Single cell RNA sequencing decodes cellular heterogeneity and identifies prognostic immune signatures in bladder cancer microenvironment.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer is a common urinary system malignancy with a complex immune microenvironment that affects treatment outcomes. Single-cell RNA sequencing technology offers new opportunities to understand cellular heterogeneity within tumors, but systematic analysis of immune-related genes in bladder cancer remains limited.
methodsWe performed multi-omics analysis on bladder cancer samples using TCGA database analysis, single-cell RNA sequencing, cell clustering, immune gene expression analysis, and network pharmacology to study cellular heterogeneity and potential therapeutic targets.
resultsWe identified 8 upregulated immune genes significantly associated with poor survival: CCL20, IL17RB, IL37, PLAU, INSL4, KNG1, SLURP1, and PAEP. Single-cell analysis revealed major cell types including B cells, T cells, dendritic cells, epithelial cells, fibroblasts, mast cells, monocytes, and smooth muscle cells. We identified 5 distinct fibroblast subgroups and 10 T cell subgroups with different functional characteristics. Network pharmacology analysis of the PLAU gene showed that traditional Chinese medicine compounds had good binding capacity with the PLAU protein, validated by molecular dynamics simulation.
conclusionThis study identified 8 prognosis-related bladder cancer immune genes and revealed tumor microenvironment heterogeneity. The findings, particularly the PLAU therapeutic target, provide important evidence for bladder cancer immunotherapy and personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.